anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent advances in high-resolution mapping of spatial interactions among regulatory elements support the existence of complex topological assemblies of enhancers and promoters known as enhancer-promoter hubs or cliques. Yet, organization principles of these multi-interacting enhancer-promoter hubs and their potential role in regulating gene expression in cancer remain unclear. Here, we systematically identify enhancer-promoter hubs in breast cancer, lymphoma, and leukemia. We find that highly interacting enhancer-promoter hubs form at key oncogenes and lineage-associated transcription factors potentially promoting oncogenesis of these diverse cancer types. Genomic and optical mapping of interactions among enhancer and promoter elements further show that topological alterations in hubs coincide with transcriptional changes underlying acquired resistance to targeted therapy in T cell leukemia and B cell lymphoma. Together, our findings suggest that enhancer-promoter hubs are dynamic and heterogeneous topological assemblies with the potential to control gene expression circuits promoting oncogenesis and drug resistance.
OBJECTIVES: To develop and validate a predictive method for axillary lymph node (ALN) metastasis of breast cancer by using radiomics based on mammography and MRI.
MATERIALS AND METHODS: A retrospective analysis of 492 women from center 1 (The affiliated Hospital of Qingdao University) and center 2 (Yantai Yuhuangding Hospital) with primary breast cancer from August 2013 to May 2021 was carried out. The radscore was calculated using the features screened based on preoperative mammography and MRI from the training cohort of Center 1 (n = 231), then tested in the validation cohort (n = 99), an internal test cohort (n = 90) from Center 1, and an external test cohort (n = 72) from Center 2. Univariate and multivariate analyses were used to screen for the clinical and radiological characteristics most associated with ALN metastasis. A combined nomogram was established in combination with radscore that predicted the clinicopathological and radiological characteristics. Calibration curves were used to test the effectiveness of the combined nomogram. The receiver operating characteristic (ROC) curve was used to evaluate the performance of the combined nomogram and then compare with the clinical and radiomic models. The decision curve analysis (DCA) value was used to evaluate the combined nomogram for clinical applications.
RESULTS: The constructed combined nomogram incorporating the radscore and MRI-reported ALN metastasis status exhibited good calibration and outperformed the radiomics signatures in predicting ALN metastasis (area under the curve [AUC]: 0.886 vs. 0.846 in the training cohort; 0.826 vs. 0.762 in the validation cohort; 0.925 vs. 0.899 in the internal test cohort; and 0.902 vs. 0.793 in the external test cohort). The combination nomogram achieved a higher AUC in the training cohort (0.886 vs. 0.786) and the internal test cohort (0.925 vs. 0.780) and similar AUCs in the validation (0.826 vs. 0.811) and external test (0.902 vs. 0.837) cohorts than the clinical model.
CONCLUSION: A combined nomogram based on mammography and MRI can be used for preoperative prediction of ALN metastasis in primary breast cancer.
Electrostimulation was performed with a Kegel 8 home elektrostymulator. The subjects were prescribed two electrostimulation programs: PO3 in the morning and PO10 in the evening. The duration of the PO3 program was 45 minutes, and was intended for general strengthening of the pelvic floor muscles. The duration of the PO10 program is 40 minutes. and it is prescribed for stress incontinence. Duration of interventions 4 week.
Cerebral palsy (CP) is the most prevalent physical disabilities originating in childhood. Crouch gait is a common gait abnormality in patients with cerebral palsy, which is common treated with hamstring lengthening. This surgery can alter mechanical property of lower limb and affected ability of generating force in hamstring, leading changes in functional activities. Therefore, the first aim of this study is to investigate the effects of hamstring lengthening on pelvis and hip control while performing functional activity, including level walking and sit-to-stand.

Gait or motion analysis has been used widely in the diagnosis of patients with locomotor pathology and the subsequent planning and assessment of treatment. Ten subjects diagnosed with spastic diplegic cerebral palsy and crouch gait will be recruited and ten healthy controls will be recruited in this study with inform consents. Detailed physical examination and motion analysis experiments will be performed in normal group and in spastic diplegic patients before the hamstring lengthening and follow ip after six months. The subjects would be asked to perform level walking with self-selected pace and sit-to-stand from an armless chair. For each test, subjects would repeat at least 5 times, with their kinematic, kinetic and EMG data collected simultaneously. With thorough analysis and comparison of these data, it is hoped that a reference in clinical decision of hamstring lengthening can be established, and a complete knowledge of the effects after hamstring lengthening, which will be helpful for future clinical rehabilitation.
The invention provides a shellac root canal filling agent, and relates to an essential preparation which is filled in a final permanent root canal after tooth impairment. The shellac root canal filling agent comprises shellac, borneol, barium sulfate and alcohol. The shellac root canal filling agent has the characteristics that the shellac is an ideal matrix, has good closure property, filling property, insulation property and an anti-static function and the unique characteristics of powerfully packaging, fixing, freezing and sealing micro-fine gaps and residual bacterial toxin cells and the like in the tooth root canal so as to form compact and firm chrysophoron, is capable of preventing the tooth root canal from liquefying and stopping the survival and development conditions of the bacterial toxin cells, has no volume change after being dry, and does not easily cause secondary infection, so that the root canal has stable internal environments, and the purpose of permanently preserving offending teeth is achieved; borneol has the functions of clearing heat, stopping pain, diminishing inflammation, resisting bacteria, preventing rotting, deodorizing, emitting fragrance and inducing resuscitation; barium sulfate is a developing agent and has an X-ray radiation resistant function; alcohol is a solvent for the shellac and borneol and has very strong permeability and penetrating power and the effects of sterilization, disinfection, rotting prevention or protein solidification. The components have good effects through combination. The formula is simple and easy to prepare. The shellac root canal filling agent has no toxic or side effects and is simple, safe, reliable and effective to use.
Drinking alcohol and cigarette smoking are closely associated and use of one often leads to the use of the other. Also, since tobacco-related illness is the number one cause of death among recovered alcoholics it is imperative that we provide strong evidence-based treatment options for this population. Since smoking can be a strong trigger to drink in those who are dependent on both alcohol and tobacco, treating both at the same time may result in better treatment outcomes. This study will examine the efficacy of starting smoking cessation treatment while patients are in residential treatment for alcohol dependence, or outpatient in the Alcohol Research and Treatment Clinic. It will compare the effectiveness of varenicline, the most effective medication for smoking cessation with placebo. Both groups will receive weekly cessation counselling and support by a trained research analyst. We will measure abstinence from smoking at the end of the 12-week treatment period and again after 6-months to determine longer-term smoking cessation.
Lisdexamfetamine dimesylate capsules:

  * Capsules 10 mg: Hard gelatin capsule with EEC pink opaque body and EEC pink opaque cap. Imprinted APO L10 in black ink. White to off-white granular fill.
  * Capsules 20 mg: Hard gelatin capsule with ivory opaque body and ivory opaque cap. Imprinted APO L20 in black ink. White to off-white granular fill.
  * Capsules 30 mg: Hard gelatin capsule with white opaque body and orange opaque cap. Imprinted APO L30 in black ink. White to off-white granular fill.
  * Capsules 40 mg: Hard gelatin capsule with white opaque body and dark green opaque cap. Imprinted APO L40 in black ink. White to off-white granular fill.
  * Capsules 50 mg: Hard gelatin capsule with white opaque body and light blue opaque cap. Imprinted APO L50 in black ink. White to off-white granular fill.
  * Capsules 60 mg: Hard gelatin capsule with aqua blue opaque body and aqua blue opaque cap. Imprinted APO L60 in black ink. White to off-white granular fill.
  * Capsules 70 mg: Hard gelatin capsule with light blue opaque body and medium orange opaque cap. Imprinted APO L70 in black ink. White to off-white granular fill.
The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or, alternatively, to enhance cognitive function including Alzheimer's Disease, Idiopathic Dementia, and Traumatic Brain Injury. The methods of the present invention include the perispinal administration of etanercept. For the purposes of this patent “perispinal” is to be considered as referring to “perispinal extrathecal;” therefore direct intrathecal administration is excluded. Perispinal administration leads to enhanced delivery of etanercept to the brain in a therapeutically effective amount, via the vertebral venous system and/or the cerebrospinal fluid. Delivery of etanercept to the brain utilizing the methods of the present invention includes the use of the vertebral venous system to deliver etanercept to the brain via retrograde venous flow. Physical maneuvers are used to enhance delivery of etanercept to the brain via this route.
Asthma patients will be diagnosed according to a clinical history of wheezing, cough, chest tightness or shortness of breath, as well as the presence of BHR (cumulative dose caus¬ing a 20% decrease in FEV1), based on the GINA guidelines. None of them had a history of COPD, or previous doctor-diagnosed ACO. All subjects had not used any oral or/and inhaled corticosteroid (ICS) in the previous 12 weeks. The included patients with asthma had initial diagnosis and were under uncontrolled stage.
Participants will be women who are nearing menopause based on age (42-52 y) but have normal menstrual cycles. Participants will be randomized to receive monthly injections of placebo or a study drug that reduces sex hormones (GnRH agonist) for 24 weeks. Women who receive GnRH agonist will be further randomized to no exercise or a supervised exercise program. Thus, the 3 treatment groups are: placebo, GnRH agonist, GnRH agonist+exercise. The investigators will measure changes in calories burned during physical activity, sleep, rest, and after a meal after 3 and 6 months of hormone suppression using doubly-labeled water and room calorimetry. Other measures include food intake estimated from food records; body composition measured by dual-energy x-ray absorptiometry (DXA); glucose and insulin responses to an oral glucose tolerance test; and markers of inflammation in the blood.
Spinal cord injury (SCI) is a complex neurodegenerative pathology that consistently harbours a poor prognostic outcome. At present, there are few therapeutic strategies that can halt neuronal cell death and facilitate functional motor recovery. However, recent studies have highlighted the Wnt pathway as a key promoter of axon regeneration following central nervous system (CNS) injuries. Emerging evidence also suggests that the temporal dysregulation of Wnt may drive cell death post-SCI. A major challenge in SCI treatment resides in developing therapeutics that can effectively target inflammation and facilitate glial scar repair. Before Wnt signalling is exploited for SCI therapy, further research is needed to clarify the implications of Wnt on neuroinflammation during chronic stages of injury. In this review, an attempt is made to dissect the impact of canonical and non-canonical Wnt pathways in relation to individual aspects of glial and fibrotic scar formation. Furthermore, it is also highlighted how modulating Wnt activity at chronic time points may aid in limiting lesion expansion and promoting axonal repair.
A system and method for establishing a healthcare network across small businesses whereby two or more small businesses and one or more healthcare insurance providers are enrolled in a small business employee healthcare network. The one or more healthcare insurance providers then offer one or more healthcare insurance plans through the small business employee healthcare network at initial bid prices. Employees of the enrolled small businesses are then provided an opportunity to view the one or more healthcare insurance plan offers. Interested employees of the enrolled small businesses then opt into one or more of the one or more healthcare insurance plan offers through the small business employee healthcare network. As the number, and/or the profile, of the employees that opt into a given one of the one or more healthcare insurance plan offers increases and/or changes, and/or in response to bids from enrolled competitor healthcare insurance providers, the one or more healthcare insurance providers can change the bid prices for the one or more healthcare insurance plan offers. After a specified time period, the healthcare insurance provider having offered the lowest bid is contracted to provide the one or more healthcare insurance plans, at the lowest bid price, to the employees that opted in.
The invention discloses application of combination of tacrolimus and fluconazole in preparing antifungal drugs. According to the invention, static and dynamic combined antifungal effects of combination of tacrolimus and fluconazole to common non-albicans candida species are researched by various methods. The researches show that combination of tacrolimus and fluconazole has a remarkable synergic antifungal effect to common non-albicans candida species (candida glabrata and candida krusei). Predictably, combination of tacrolimus and fluconazole can be used for preparing antifungal drugs. According to the invention, tacrolimus and fluconazole are applied in a combined way to enhance the antimicrobial activity of fluconazole to non-albicans candida species so as to generate the synergic antifungal effect. Combination of tacrolimus and fluconazole can reverse the drug resistance of non-albicans candida species to fluconazole, thereby providing a research direction for development of new drugs and new use of old drugs.
Patient will receive matching placebo orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
Vaccines and methods of inoculation for conferring immunity to  Cryptococcus  infection are disclosed. Strains of  Cryptococcus  fungi, including  Cryptococcus neoformans  and  Cryptococcus gattii , can be administered to a human or animal subject via inhalation.  Cryptococcus  fungi that can be used to confer immunity can comprise one or more mutations in genes that contribute to chitosan production, such as genes encoding a chitin deacetylase (cda), a chitin synthase (chs) and/or a regulator of chitin synthase (csr). Inhalation administration of heat-killed  Cryptococcus  harboring deletions in cda1, cda2 and cda3 genes can confer immunity. In a murine model system, inhalation administration of  Cryptococcus neoformans  harboring deletions in cda1, cda2 and cda3 genes conferred immunity against subsequent exposure to wild type  Cryptococcus neoformans  in 100% of test animals. Inhalation administration of heat-killed  Cryptococcus  grown under conditions leading to reduced chitosan production can also confer immunity.
Trimethoprim (TMP) 160 mg/sulfamethoxazole (SMX) 800 mg once daily has been shown to increase lamivudine exposure (AUC). No change in dose of either drug is recommended. The effect of higher doses of TMP/SMX on lamivudine pharmacokinetics has not been investigated (see CLINICAL PHARMACOLOGY).

Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another. Therefore, use of EPZICOM in combination with zalcitabine is not recommended.

See CLINICAL PHARMACOLOGY for additional drug interactions.
The leading cause of cancer-related death is lung cancer, with metastasis being the most common cause of death. To elucidate the role of macrophages in lung cancer and angiogenesis processes, we established an in vitro co-culture model of A549 or HUVEC with THP-1 cells that polarized to M2c macrophages with hydrocortisone. The proteasome inhibitors bortezomib and ixazomib were investigated for their effects on proliferation, invasion, migration, metastasis, and angiogenesis pathways. The effects of bortezomib and ixazomib on gene expression in gene panels, including crucial genes related to angiogenesis and proteasomes, were investigated after the co-culture model to determine these effects at the molecular level. In conclusion, bortezomib and ixazomib showed antiproliferative effects in both cells, as well as in M2c macrophage co-culture. M2c macrophages also increased invasion in A549 cells and both invasion and migration in HUVEC. mRNA expression upregulation, specifically in the NFKB and VEGF genes, supported the metastatic and angiogenic effects found in A549 and HUVEC with M2c macrophage co-culture. Additionally, bortezomib inhibited the VEGFB pathway in HUVEC and NFKB1 in A549 cells. The significant findings obtained as a result of this study will provide information regarding angiogenesis induced by M2 macrophages.
The present invention relates to a biodegradable biocide (a modified Benzalkonium Chloride -Diallyl disulfide Oxide Complex) which has no impact on the ecosystem, the active ingredient of this disinfectant comprising the formula: (see formula). The main steps for the manufacture of the present invention are: carefully selecting the Liliaceae-related family raw materials. Washing the bulbs and tubers, which are thoroughly ground for obtaining an extract with an Azeotropic mixture (ethanol-water 1:1). Subsequently adding glucose-carbonyl diamide and benzalkonium chloride. Stirring and filtering the mixture and monitoring the pH thereof so that a range of from about 6 to about 8 is obtained. The final product thus obtained has the general formula: C35H62O5N3S2C1, which is characterized by an interaction of glucoside-corresponding hydrogen bridges with Allicin.
Lamotrigine Extended-Release Tablets are indicated as adjunctive therapy for PGTC and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. Safety and effectiveness of Lamotrigine Extended-Release Tablets for any use in patients younger than 13 years have not been established.

Immediate-release lamotrigine is indicated as adjunctive therapy in patients aged 2 years and older for partial-onset seizures, the generalized seizures of Lennox-Gastaut syndrome, and PGTC seizures.

Safety and efficacy of immediate-release lamotrigine used as adjunctive treatment for partial-onset seizures were not demonstrated in a small, randomized, double-blind, placebo-controlled withdrawal trial in very young pediatric patients (aged 1 to 24 months). Immediate-release lamotrigine was associated with an increased risk for infectious adverse reactions (lamotrigine 37%, placebo 5%), and respiratory adverse reactions (lamotrigine 26%, placebo 5%). Infectious adverse reactions included bronchiolitis, bronchitis, ear infection, eye infection, otitis externa, pharyngitis, urinary tract infection, and viral infection. Respiratory adverse reactions included nasal congestion, cough, and apnea.

Juvenile Animal Data 

In a juvenile animal study in which lamotrigine (oral doses of 0, 5, 15, or 30 mg/kg) was administered to young rats from postnatal day 7 to 62, decreased viability and growth were seen at the highest dose tested and long-term neurobehavioral abnormalities (decreased locomotor activity, increased reactivity, and learning deficits in animals tested as adults) were observed at the 2 highest doses. The no-effect dose for adverse developmental effects in juvenile animals is less than the human dose of 400 mg/day on a mg/m 2 basis.
An object container apparatus includes a housing, a sensor sheet, and one or more computer processors coupled to the sensor sheet. The housing comprises one or more interior surfaces forming a cavity. The sensor sheet is positioned within the cavity and comprises one or more arrays of capacitive touch pads. The one or more arrays of capacitive touch pads are arranged substantially parallel to each other in order to form a space within the cavity where an object can be inserted. The one or more computer processors are coupled to the one or more arrays of capacitive touch pads and configured to process capacitance measurements derived from the one or more arrays of capacitive touch pads. The object container apparatus functions to detect an object in the space via processing of capacitance measurements by the one or more computer processors.
Gaucher disease is one of the most common lysosomal storage disorders. Osteonecrosis is a principal clinical manifestation of Gaucher disease and often leads to joint collapse and fractures. T1-weighted (T1w) modality in MRI is widely used to monitor bone involvement in Gaucher disease and to diagnose osteonecrosis. However, objective and quantitative methods for characterizing osteonecrosis are still limited. In this work, we present a deep learning-based quantification approach for the segmentation of osteonecrosis and the extraction of characteristic parameters. We first constructed two independent U-net models to segment the osteonecrosis and bone marrow unaffected by osteonecrosis (UBM) in spine and femur respectively, based on T1w images from patients in the UK national Gaucherite study database. We manually delineated parcellation maps including osteonecrosis and UBM from 364 T1w images (176 for spine, 188 for femur) as the training datasets, and the trained models were subsequently applied to all the 917 T1w images in the database. To quantify the segmentation, we calculated morphological parameters including the volume of osteonecrosis, the volume of UBM, and the fraction of total marrow occupied by osteonecrosis. Then, we examined the correlation between calculated features and the bone marrow burden score for marrow infiltration of the corresponding image, and no strong correlation was found. In addition, we analyzed the influence of splenectomy and the interval between the age at first symptom and the age of onset of treatment on the quantitative measurements of osteonecrosis. The results are consistent with previous studies, showing that prior splenectomy is closely associated with the fractional volume of osteonecrosis, and there is a positive relationship between the duration of untreated disease and the quantifications of osteonecrosis. We propose this technique as an efficient and reliable tool for assessing the extent of osteonecrosis in MR images of patients and improving prediction of clinically important adverse events.